[{"address1": "200 Arsenal Yards Boulevard", "address2": "Suite 230", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 186, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 49, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 75000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 44, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1075600, "exercisedValue": 457971, "unexercisedValue": 20455824}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 671200, "exercisedValue": 249766, "unexercisedValue": 5641756}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 60, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 614498, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen V. Chiniara Esq., J.D.", "age": 64, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 640345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723600, "exercisedValue": 0, "unexercisedValue": 4995031}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 31.96, "open": 35.67, "dayLow": 34.77, "dayHigh": 39.95, "regularMarketPreviousClose": 31.96, "regularMarketOpen": 35.67, "regularMarketDayLow": 34.77, "regularMarketDayHigh": 39.95, "beta": 2.222, "forwardPE": -12.763754, "volume": 2884132, "regularMarketVolume": 2884132, "averageVolume": 535468, "averageVolume10days": 571330, "averageDailyVolume10Day": 571330, "bid": 39.35, "ask": 39.52, "bidSize": 200, "askSize": 200, "marketCap": 2419971328, "fiftyTwoWeekLow": 9.6, "fiftyTwoWeekHigh": 45.31, "priceToSalesTrailing12Months": 30.47324, "fiftyDayAverage": 33.7882, "twoHundredDayAverage": 28.849026, "currency": "USD", "enterpriseValue": 1527487104, "profitMargins": -1.94667, "floatShares": 40124008, "sharesOutstanding": 61358300, "sharesShort": 10141726, "sharesShortPriorMonth": 9867211, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.16530001, "heldPercentInsiders": 0.01345, "heldPercentInstitutions": 1.11888, "shortRatio": 19.99, "shortPercentOfFloat": 0.1858, "impliedSharesOutstanding": 61358300, "bookValue": 11.592, "priceToBook": 3.4023464, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -154591008, "trailingEps": -2.51, "forwardEps": -3.09, "pegRatio": -5.59, "enterpriseToRevenue": 19.235, "enterpriseToEbitda": -8.961, "52WeekChange": 0.418553, "SandP52WeekChange": 0.2553556, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "KYMR", "underlyingSymbol": "KYMR", "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "firstTradeDateEpochUtc": 1598016600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fe087242-38df-325c-aac8-26165faa63ce", "messageBoardId": "finmb_542085131", "gmtOffSetMilliseconds": -14400000, "currentPrice": 39.44, "targetHighPrice": 112.0, "targetLowPrice": 30.0, "targetMeanPrice": 51.07, "targetMedianPrice": 45.5, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 14, "totalCash": 520544000, "totalCashPerShare": 8.484, "ebitda": -170463008, "totalDebt": 87021000, "quickRatio": 9.309, "currentRatio": 9.571, "totalRevenue": 79413000, "debtToEquity": 12.236, "revenuePerShare": 1.291, "returnOnAssets": -0.146, "returnOnEquity": -0.26354, "freeCashflow": -110169376, "operatingCashflow": -98449000, "revenueGrowth": 0.087, "grossMargins": -1.46399, "ebitdaMargins": -2.1465402, "operatingMargins": -5.1429996, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-09"}]